v3.25.2
Segment information - Schedule of Segment Financial Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Total revenue $ 97,964   $ 75,400   $ 191,845 $ 145,902
Cost of revenue from sale of therapies (1,040)   (1,707)   (1,871) (1,953)
R&D expenses (69,008)   (51,072)   (125,476) (108,531)
SG&A expenses (42,791)   (38,638)   (82,989) (77,925)
Net loss (10,300) $ 5,023 (11,616) $ (24,436) (5,277) (36,052)
Reportable segment            
Segment Reporting Information [Line Items]            
Total revenue 97,964   75,400   191,845 145,902
Cost of revenue from sale of therapies (1,040)   (1,707)   (1,871) (1,953)
Other segment expense, net (11,568)   (9,901)   (17,731) (21,197)
Net loss (10,300)   (11,616)   (5,277) (36,052)
Reportable segment | External R&D            
Segment Reporting Information [Line Items]            
R&D expenses (47,673)   (32,377)   (85,604) (73,716)
Reportable segment | PRAME programs | External R&D            
Segment Reporting Information [Line Items]            
R&D expenses (20,678)   (21,932)   (37,983) (48,632)
Reportable segment | Tebentafusp programs | External R&D            
Segment Reporting Information [Line Items]            
R&D expenses (10,417)   (4,557)   (18,407) (10,451)
Reportable segment | Infectious disease programs | External R&D            
Segment Reporting Information [Line Items]            
R&D expenses (1,325)   (1,439)   (2,730) (3,685)
Reportable segment | All other external clinical and preclinical costs | External R&D            
Segment Reporting Information [Line Items]            
R&D expenses (15,253)   (4,449)   (26,484) (10,948)
Reportable segment | Salaries and other employee related cost            
Segment Reporting Information [Line Items]            
R&D expenses (12,907)   (12,221)   (23,950) (21,975)
SG&A expenses (12,827)   (10,481)   (25,045) (25,321)
Reportable segment | Other SG&A expenses            
Segment Reporting Information [Line Items]            
SG&A expenses $ (22,249)   $ (20,329)   $ (42,921) $ (37,792)